VOLTAREN SR TABLET (EXTENDED-RELEASE)

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

DICLOFENAC SODIUM

Prieinama:

NOVARTIS PHARMACEUTICALS CANADA INC

ATC kodas:

M01AB05

INN (Tarptautinis Pavadinimas):

DICLOFENAC

Dozė:

100MG

Vaisto forma:

TABLET (EXTENDED-RELEASE)

Sudėtis:

DICLOFENAC SODIUM 100MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

100/250

Recepto tipas:

Prescription

Gydymo sritis:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Produkto santrauka:

Active ingredient group (AIG) number: 0114417001; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

1997-05-07

Prekės savybės

_VOLTAREN_
_ _
_and VOLTAREN SR diclofenac sodium _
_ Page 1 of 50_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
VOLTAREN
®
PR
VOLTAREN
® SR
(Diclofenac sodium suppositories)
(Diclofenac sodium slow-release tablets)
Slow-Release Tablets, 100 mg, for oral use
Suppositories, 50 mg, for rectal use
Mfr. Std.
Non-Steroidal Anti-Inflammatory Drug (NSAID)
Novartis Pharmaceuticals Canada Inc.
Date of Initial Authorization:
385 Bouchard Blvd.,
July 5, 1989
Dorval, Quebec H9S 1A9
www.novartis.ca
Date of Revision:
JUN 08, 2022
Control no. 260554
VOLTAREN and VOLTAREN SR are registered trademark.
_ _
_VOLTAREN_
_ _
_and VOLTAREN SR diclofenac sodium _
_ Page 2 of 50_
RECENT MAJOR LABEL CHANGES
3 SERIOUS WARNINGS AND PRECAUTIONS BOX-
Risk in Pregnancy
10/2021
7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests,
_Pregnancy_
10/2021
7 WARNINGS AND PRECAUTIONS, Skin, _Serious skin reactions _
10/2021
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women
10/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES..............................................................................................2
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
................................................................................................................4
1.1
Pediatrics
............................................................................................................4
1.2
Geriatrics.............................................................................................................5
2
CONTRAINDICATIONS
...................................................................................................5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
..................................................